RT Journal Article
SR Electronic
T1 IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e006821
DO 10.1136/jitc-2023-006821
VO 11
IS 7
A1 Rozeman, Elisa A
A1 Versluis, Judith M
A1 Sikorska, Karolina
A1 Hoefsmit, Esmée P
A1 Dimitriadis, Petros
A1 Rao, Disha
A1 Lacroix, Ruben
A1 Grijpink-Ongering, Lindsay G
A1 Lopez-Yurda, Marta
A1 Heeres, Birthe C
A1 van de Wiel, Bart A
A1 Flohil, Claudie
A1 Sari, Aysegul
A1 Heijmink, Stijn W T P J
A1 van den Broek, Daan
A1 Broeks, Annegien
A1 de Groot, Jan Willem B
A1 Vollebergh, Marieke A
A1 Wilgenhof, Sofie
A1 van Thienen, Johannes V
A1 Haanen, John B A G
A1 Blank, Christian U
YR 2023
UL http://jitc.bmj.com/content/11/7/e006821.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.